Hutchmed (china) Share Discussion Threads

[lauders] 12/12/2024 07:44

Good news again. Will it have any effect on the share price?

Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive non‑small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI.

[fillipe] 09/12/2024 18:05

HCM deserves more than the only +4p of the day, even after also recovering from a poor opening.
Folks will surely catch on as the days go by, if they have the insight.

f

[1jat] 03/12/2024 14:10

An early gift from the Chinese regulator giving conditional approval for Fruq + Sintilimab (another Lilly development with Innovent).
Q what will the commercial strategy be for this combination
Q what will Takeda do? It has its own PD-1 if it does not want to use Sintilimab.

The company launch runway had this one ahead of Sovlep despite Sov being submitted three months earlier….I am expecting Sovlep, Taz and Savo approvals about 1 year to 15m after submission. Hopefully Sovlep comes in Q1 25.

[fillipe] 02/12/2024 17:39

A nice modest uptick into the close today.

f

[shaker45] 29/11/2024 09:03

Just more sellers than reasons to buy. Markets looking toppy, more negative economic news from China. Probably nothing hcm specific.

[fillipe] 29/11/2024 08:52

What a differenve a week can make ... any thoughts on why the steady drift downwards?

f

[fillipe] 22/11/2024 10:08

Looking very good for the going forward.

f

[lauders] 22/11/2024 04:58

Good news from HCM today: HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

They also received a milestone payment from Takeda as a consequence.

[fillipe] 20/11/2024 09:58

Reason for today's rise is perhaps due to the RNS release of only a very short time ago.



Woiuld appear to be a quite significat appointment.

f

[fillipe] 20/11/2024 09:07

Nice 6.5% uptick at the start of today.
Bid/Ask totals 21.2k v 17.9k, as I type.

f

[dbadvn] 19/11/2024 12:57

Good entry point.

[fillipe] 19/11/2024 12:33

Took some again today at near 265p.
The last lot did well and forecasts appear enthusiastic for the going forward, with a recent tp of 539p.

Good wishes to all.

f

[1jat] 12/11/2024 07:28

AZ has reported Orpathys sales of $36m for the 9m to end September.
This is consistent with the H1 run rate and FY sales should be close to $50m.

The Savannah read out was the first item in the pipeline update. HCM has stated in the November corporate presentation that they expect AZ to submit the US NDA in 2024. They also mention accelerated approval, so we may see an approval late in 2025, both events are likely to trigger milestone payments followed by sales milestones and royalties in 2026.

[1jat] 31/10/2024 17:52

Slightly disappointing Q3 sales by Takeda of $73m down from 80m in Q2.

On the upside, total sales exceed $200m triggering a $20m payment, the first commercial milestone payment under the Takeda agreement.
It looks like 2024 sales will be around $300m with some early sales from Europe and Japan to be added to a further 75m from the US.

[1jat] 17/10/2024 13:32

Arguably both cash flow + and - lead to M&A - one as the major party and one as the minor party.

There are a lot of biotechs in China and there are significant efficiencies possible across pipeline assets, sales and general administration. New money is hard to raise but mergers are likely to be encouraged by the mainland to build some national champions (globally China cos are not in the big pharma league - that should change).

If CKHH is willing to back HCM issuing new equity or taking on some debt, then it should be possible for HCM to take the lead on some M&A deals and grow inorganically - that is how big Pharma got to be big rather than organic growth.

Pre-commercial deals - will come with more uncertainty but the target will bring some cash and R&D capabilities. The main economies will come from pushing more volume through the factory and sales channels when the acquired products are approved.

Commercial stage deals - Should generate value for both shareholders due to the large synergies…..balance sheet management will drive the cash/equity offer and debt levels taken on.

I dont think HCM has the management to do a significant merger at the moment, so if they are to be on the front foot I would expect a new CEO and a strategy director to be appointed first.

[dbadvn] 16/10/2024 12:18

Won’t affect the share price. Market expects only positive clinical results , only reacts to the negative.

It’s all about getting to cash flow positive. No more free money . Cash flow positive means survival and further growth. Not cash flow positive means takeover or merger. We will know which in the next 12 months or so.

[lauders] 16/10/2024 05:45

Further good news: HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Will hopefully get past 300p again. Perhaps it may actually stay above for once!

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, October 16, 2024: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:​HCM; HKEX:​13) today announces positive high-level results from the SAVANNAH Phase II trial that showed TAGRISSO® (osimertinib) plus ORPATHYS® (savolitinib) demonstrated a high, clinically meaningful and durable objective response rate (“ORR”) for patients with epidermal growth factor receptor-mutated (“EGFRm”) non-small cell lung cancer (“NSCLC”) with high levels of MET overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO®. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities. In 2023, TAGRISSO® plus ORPATHYS® received Fast Track designation from the US Food and Drug Administration (FDA) in this setting.

[lauders] 03/10/2024 04:07

More good news!

HUTCHMED’s ELUNATE® (fruquintinib) Listed with Full Subsidy in the Hong Kong Hospital Authority Drug Formulary

Yet, currently down 7.70% in HK although the news doesn't seem to be showing on this page at THIS time. No doubt it will show and then there will be a change in sentiment?

[fillipe] 02/10/2024 07:27

HCM + 7.48% at the start of today.
Lowest ask on show; 317p.

f

[lauders] 24/9/2024 07:56

Good news!

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

[1jat] 30/8/2024 17:25

I dont expect anything to happen quickly - but I hope this triggers a thought that it might be a good idea to separate the roles of CEO and CSO……and they need to appoint some new management to both roles.

I would also like CKHH to review its strategy for HCM. I suspect HCM shareholders would be materially better off if it was part of a larger organisation where the commercial teams can be rationalised / leveraged along with the pipeline better prioritised. That could mean bringing in new management and then acquiring other businesses, or selling to a rival.

[dbadvn] 30/8/2024 10:13

1jat.

I agree - this is yet another management screw up - they should not have waited so long when they must have known the results were not acceptable , and talking it up at the HY results is just inexplicable. very poorly handled.

Not the first time ; HCM suceeds technically, despite its management ......

[1jat] 30/8/2024 09:52

Waldron - what is your view on the RNS?
From my perspective it is disappointing, but the problem with OS was in plain sight. I am disappointed that it has been a lost 18m while waiting for a negative view from the regulator.

What this does call into question is management’s judgement…..they were talking this up at the HY results but the issues must have been known and the prospects worsening.

Hopefully there will be good news from Japan shortly and positive news from the outstanding China regulatory submissions…..
From a management credibility perspective it is important that they get the ITP and EMC approvals and the extension to Savolitinib.